Drug companies trying to find patients with certain types of (rare) cancers, so they are trying to get more people tested. -- at their insurers' expense. This is good for the patients if it can improve treatment options, but kind of annoying that the very wealthy companies are able to get someone else to pick up the tab.

https://www.bloomberg.com/news/articles/2018-...-challenge